Skip to content

Alumis Inc. ALMS Free cash flow yield

Free cash flow yield at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
9.6%-0.9pp
Amgen logo
AmgenAMGN
4.5%-2.0pp
Oruka Therapeutics, Inc. logo
Oruka Therapeutics, Inc.ORKA
-3.8%
ANI Pharmaceuticals logo
ANI PharmaceuticalsANIP
11.1%+6.5pp
Celldex Therapeutics logo
Celldex TherapeuticsCLDX
-10.7%-2.2pp
Immunome logo
ImmunomeIMNM
-8.3%-3.4pp

Other financials

Income statement

See full
Revenue$1.7M-90.0%
Operating income-$98.4M+3.1%
Net income-$93.1M+6.0%
EPS (diluted)-$0.74+59.3%

Balance sheet

See full
Cash & equivalents$63.9M-50.3%
Total debt$35.7M+1,881%
Total equity$567.0M+237%
Total assets$671.6M+157%

Cash flow

See full
Operating cash flow-$87.1M-8.4%
CapEx$164.0K+343%
Free cash flow-$87.2M-8.5%

Valuation

See full
Market cap$3.12B+739%
Enterprise value$3.1B+1,238%
P/S371.9×

Profitability

See full
Operating margin-5,364%
Net margin-2,825.7%
FCF margin-4,487.4%

Returns & leverage

See full
Return on equity-64.6%
Debt / equity0.1×+0.1×
Current ratio7.5×+3.8×

Where this comes from

Calculated from Alumis Inc.’s reported figures.

Based on trailing twelve months.

The official record: Alumis Inc.’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about Alumis Inc.'s free cash flow yield.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Alumis Inc.'s free cash flow yield?
Alumis Inc. (ALMS) reported free cash flow yield of -13.5% in Q1 2026.
How has Alumis Inc.'s free cash flow yield changed year-over-year?
Alumis Inc.'s free cash flow yield increased by 84.6% year-over-year, from -87.6% to -13.5%.
What does free cash flow yield mean?
Trailing-twelve-month free cash flow divided by market capitalization at the quarter end. The cash return the business generates relative to its market price.